Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paola Barboro

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Biomolecules|January 23, 2024
Identification of Molecular Markers Associated with Prostate Cancer Subtypes: An Integrative Bioinformatics ApproachIlaria Granata, Paola Barboro
Cancer Letters|July 13, 2014
Emerging roles of heterogeneous nuclear ribonucleoprotein K (hnRNP K) in cancer progressionPaola Barboro, Nicoletta Ferrari, Cecilia Balbi
Plos One|July 19, 2012
The role of nuclear matrix proteins binding to matrix attachment regions (Mars) in prostate cancer cell differentiationPaola Barboro, Erica Repaci, Cristina D'Arrigo, et al.
Cancer Treatment and Research Communications|October 22, 2020
Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational studyCarlo Cattrini, Matteo Capaia, Francesco Boccardo, et al.
Plos One|November 16, 2013
Androgen receptor activity is affected by both nuclear matrix localization and the phosphorylation status of the heterogeneous nuclear ribonucleoprotein K in anti-androgen-treated LNCaP cellsPaola Barboro, Luana Borzì, Erica Repaci, et al.
Experimental Cell Research|December 23, 2009
Organization of the lamin scaffold in the internal nuclear matrix of normal and transformed hepatocytesPaola Barboro, Cristina D'Arrigo, Erica Repaci, et al.
International Journal of Cancer|March 26, 2009
Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a playerRoberto Benelli, Stefano Monteghirfo, Cecilia Balbi, et al.
The Prostate|February 16, 2011
Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell linesPaola Barboro, Erica Repaci, Nicoletta Ferrari, et al.
The International Journal of Biological Markers|June 21, 2022
The prognostic value of aspartate beta-hydroxylase in early breast cancerPaola Barboro, Alessandra Rubagotti, Silvia Poddine, et al.
Anticancer Research|November 29, 2005
Nuclear matrix protein expression in prostate cancer: possible prognostic and diagnostic applicationsPaola Barboro, Alessandra Rubagotti, Francesco Boccardo, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Biomolecules|January 23, 2024
Identification of Molecular Markers Associated with Prostate Cancer Subtypes: An Integrative Bioinformatics ApproachIlaria Granata, Paola Barboro
Cancer Letters|July 13, 2014
Emerging roles of heterogeneous nuclear ribonucleoprotein K (hnRNP K) in cancer progressionPaola Barboro, Nicoletta Ferrari, Cecilia Balbi
Plos One|July 19, 2012
The role of nuclear matrix proteins binding to matrix attachment regions (Mars) in prostate cancer cell differentiationPaola Barboro, Erica Repaci, Cristina D'Arrigo, et al.
Cancer Treatment and Research Communications|October 22, 2020
Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational studyCarlo Cattrini, Matteo Capaia, Francesco Boccardo, et al.
Plos One|November 16, 2013
Androgen receptor activity is affected by both nuclear matrix localization and the phosphorylation status of the heterogeneous nuclear ribonucleoprotein K in anti-androgen-treated LNCaP cellsPaola Barboro, Luana Borzì, Erica Repaci, et al.
Experimental Cell Research|December 23, 2009
Organization of the lamin scaffold in the internal nuclear matrix of normal and transformed hepatocytesPaola Barboro, Cristina D'Arrigo, Erica Repaci, et al.
International Journal of Cancer|March 26, 2009
Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a playerRoberto Benelli, Stefano Monteghirfo, Cecilia Balbi, et al.
The Prostate|February 16, 2011
Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell linesPaola Barboro, Erica Repaci, Nicoletta Ferrari, et al.
The International Journal of Biological Markers|June 21, 2022
The prognostic value of aspartate beta-hydroxylase in early breast cancerPaola Barboro, Alessandra Rubagotti, Silvia Poddine, et al.
Anticancer Research|November 29, 2005
Nuclear matrix protein expression in prostate cancer: possible prognostic and diagnostic applicationsPaola Barboro, Alessandra Rubagotti, Francesco Boccardo, et al.
Pageof 5